Australia's most trusted
source of pharma news
Thursday, 06 February 2025
Posted 4 February 2025 AM
The Top 35 PBS drugs with the biggest growth cost the Federal Government an extra $1.4 billion over the last financial year (FY), according to Expenditure and Prescriptions Report 2023-24.
Despite continuing supply issues, sales of Novo Nordisk's GLP-1 agonist Ozempic skyrocketed 94 per cent in the 2023-24 FY, costing the government an extra $138.5 million compared to the previous FY.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.